Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pfeffer

Showing results (341-350 of 513) with videos related to

Pageof 52
Sort By:
European Journal of Heart Failure|June 12, 2003
Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programmeJ McMurray, J Ostergren, M Pfeffer, et al.
Journal of Hypertension|April 7, 2007
Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system, F Turnbull, B Neal, et al.
Journal of Cardiac Failure|September 25, 1999
Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme InvestigatorsK Swedberg, M Pfeffer, C Granger, et al.
The Journal of Biological Chemistry|February 15, 1991
Phosphorylation of the proto-oncogene product eukaryotic initiation factor 4E is a common cellular response to tumor necrosis factorM W Marino, L J Feld, E A Jaffe, et al.
British Journal of Cancer|August 14, 2014
The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?P Blumenfeld, R M Pfeffer, Z Symon, et al.
The Journal of Biological Chemistry|August 2, 2013
Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathwayJo Meagan Garner, Meiyun Fan, Chuan He Yang, et al.
Endocrinology|March 30, 2026
Role of JAK-STAT Signaling Pathway in Hormonal Cancer Therapeutic Resistance and Lineage PlasticityWendy Effah, Marjana Khalil, Sanskrita Sukla, et al.
The Journal of Biological Chemistry|April 25, 1997
The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon actionL M Pfeffer, L Basu, S R Pfeffer, et al.
Journal of Cellular and Molecular Medicine|July 16, 2022
STAT3 regulates inflammatory cytokine production downstream of TNFR1 by inducing expression of TNFAIP3/A20Ricardo J Antonia, Eveliina Karelehto, Kan Toriguchi, et al.
Nature|September 15, 1999
NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinaseO N Ozes, L D Mayo, J A Gustin, et al.
Pageof 52

Showing results (341-350 of 513) with videos related to

Sort By:
Pageof 52
European Journal of Heart Failure|June 12, 2003
Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programmeJ McMurray, J Ostergren, M Pfeffer, et al.
Journal of Hypertension|April 7, 2007
Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system, F Turnbull, B Neal, et al.
Journal of Cardiac Failure|September 25, 1999
Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme InvestigatorsK Swedberg, M Pfeffer, C Granger, et al.
The Journal of Biological Chemistry|February 15, 1991
Phosphorylation of the proto-oncogene product eukaryotic initiation factor 4E is a common cellular response to tumor necrosis factorM W Marino, L J Feld, E A Jaffe, et al.
British Journal of Cancer|August 14, 2014
The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?P Blumenfeld, R M Pfeffer, Z Symon, et al.
The Journal of Biological Chemistry|August 2, 2013
Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathwayJo Meagan Garner, Meiyun Fan, Chuan He Yang, et al.
Endocrinology|March 30, 2026
Role of JAK-STAT Signaling Pathway in Hormonal Cancer Therapeutic Resistance and Lineage PlasticityWendy Effah, Marjana Khalil, Sanskrita Sukla, et al.
The Journal of Biological Chemistry|April 25, 1997
The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon actionL M Pfeffer, L Basu, S R Pfeffer, et al.
Journal of Cellular and Molecular Medicine|July 16, 2022
STAT3 regulates inflammatory cytokine production downstream of TNFR1 by inducing expression of TNFAIP3/A20Ricardo J Antonia, Eveliina Karelehto, Kan Toriguchi, et al.
Nature|September 15, 1999
NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinaseO N Ozes, L D Mayo, J A Gustin, et al.
Pageof 52